BioSpace News Archive

Hematology is defined as the diagnostic classification of cells present in the blood and resulting identification of diseases of the blood-forming organs and diseases of the blood.

Diagnostic technology has evolved at a rapid pace over the past decade, owing to significant breakthroughs in research and development.

Growing incidence of chronic and infectious diseases is anticipated to fuel demand for immunoassay.

According to the report, the global psoriatic arthritis therapeutics market was valued at US$ 6,011.7 Mn in 2017. It is projected to expand at a CAGR of 11.4% from 2018 to 2026.

Radiology has emerged as a significant tool for diagnosis of several diseases and has played an extremely powerful role in the supervision of treatment and prediction of the outcome.

Rise in the prevalence of schizophrenia, approvals for additional indications, and launch of new schizophrenia drugs are driving the schizophrenia drugs market.

With better infrastructure for research, the ability to perform sophisticated studies and analyses has become better over the years.

Single dose radiotherapy (SDRT) services have evolved in scope in oncology to meet the needs of new image-guided radiotherapy.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the reconvened Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) meeting to review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS).

Medigen, Inc. announced that it is doubling the amount of space leased at Riverside Technology Park in Frederick, Maryland to 12,000 square feet, which represents the second time the biotech company has expanded its operations at 8420 Gas House Pike within the last 36 months.